Historique du chiffre d'affaires, des bénéfices et des flux de trésorerie d'après les états financiers officiels.
Revvity, Inc. provides health sciences solutions, technologies, and services. The company offers instruments, reagents, software, subscriptions, detection and imaging technologies, extended warranties, training and services; and instruments, reagents, assay platforms and software products for early detection of common and rare conditions, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.
Voir les graphiques interactifs et les états complets → Modèle de valorisation (DCF) →
| Compte de résultat | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 | 2012-12-31 | 2011-12-31 | 2010-12-31 | 2009-12-31 | 2008-12-31 | 2007-12-31 | 2006-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Chiffre d'affaires total | $2.9B | $2.9B | $2.8B | $2.8B | $3.3B | $3.8B | $3.8B | $2.9B | $2.8B | $2.3B | $2.1B | $2.1B | $2.2B | $2.2B | $2.1B | $1.9B | $1.7B | $1.6B | $2.0B | $1.8B | $1.5B |
| Bénéfice brut | $1.5B | $1.5B | $1.3B | $1.3B | $1.8B | $2.3B | $2.0B | $1.3B | $1.3B | $1.0B | $972M | $930M | $971M | $940M | $924M | $824M | $740M | $699M | $835M | $715M | $623M |
| Marge brute % | 52.1% | 53.1% | 48.0% | 48.1% | 53.2% | 59.6% | 52.6% | 44.8% | 45.0% | 45.6% | 46.0% | 44.2% | 43.4% | 43.4% | 43.7% | 42.9% | 43.4% | 45.1% | 42.6% | 40.0% | 40.3% |
| Résultat opérationnel (EBIT) | $358M | $357M | $411M | $399M | $781M | $1.3B | $1.0B | $405M | $371M | $305M | $306M | $267M | $230M | $259M | $201M | $118M | $173M | $140M | $201M | $175M | $152M |
| Marge opérationnelle % | 12.3% | 12.5% | 14.9% | 14.5% | 23.6% | 35.0% | 27.0% | 14.1% | 13.4% | 13.5% | 14.4% | 12.7% | 10.3% | 11.9% | 9.5% | 6.1% | 10.1% | 9.0% | 10.3% | 9.8% | 9.8% |
| Résultat net | $238M | $242M | $296M | ($118M) | $569M | $943M | $728M | $228M | $239M | $113M | $234M | $212M | $158M | $168M | $68M | $1M | $384M | $86M | $128M | $133M | $117M |
| Marge nette % | 8.2% | 8.5% | 10.7% | -4.3% | 17.2% | 24.6% | 19.2% | 7.9% | 8.6% | 5.0% | 11.1% | 10.1% | 7.1% | 7.8% | 3.2% | 0.1% | 22.5% | 5.5% | 6.6% | 7.4% | 7.6% |
| EBITDA | — | $663M | $840M | $714M | $1.2B | $1.6B | $1.2B | $515M | $505M | $446M | $386M | $352M | $323M | $332M | $223M | $200M | $267M | $201M | $263M | $245M | $229M |
| Bénéfice par action (EPS) | $2.09 | $2.13 | $2.41 | $-0.95 | $4.50 | $8.08 | $6.50 | $2.04 | $2.14 | $1.02 | $2.12 | $1.87 | $1.39 | $1.48 | $0.60 | $0.01 | $3.25 | $0.73 | $1.08 | $1.10 | $0.93 |
| Actions en circulation (M) | — | 113M | 123M | 125M | 126M | 117M | 112M | 112M | 112M | 111M | 110M | 113M | 114M | 114M | 115M | 114M | 118M | 117M | 119M | 121M | 126M |
Source : rapports publics de la société (SEC). Vérifiez sur SEC EDGAR avant de vous fier à tout chiffre.
Bilans, flux de trésorerie, données trimestrielles et ratios complets dans le visualiseur interactif de RVTY. /companies/us/RVTY
Les informations de ce site sont fournies à des fins éducatives et informatives uniquement ; elles ne constituent pas un conseil en investissement. Aucun objectif de cours ni recommandation n'est publié.
About TickerBase · Data methodology & sources · Privacy · Terms